SG11201900096QA - Novel processes for preparation of soluble guanylate cyclase stimulators - Google Patents
Novel processes for preparation of soluble guanylate cyclase stimulatorsInfo
- Publication number
- SG11201900096QA SG11201900096QA SG11201900096QA SG11201900096QA SG11201900096QA SG 11201900096Q A SG11201900096Q A SG 11201900096QA SG 11201900096Q A SG11201900096Q A SG 11201900096QA SG 11201900096Q A SG11201900096Q A SG 11201900096QA SG 11201900096Q A SG11201900096Q A SG 11201900096QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- preparation
- massachusetts
- pct
- guanylate cyclase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662359453P | 2016-07-07 | 2016-07-07 | |
| PCT/US2017/040810 WO2018009597A1 (en) | 2016-07-07 | 2017-07-06 | Novel processes for preparation of soluble guanylate cyclase stimulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201900096QA true SG11201900096QA (en) | 2019-02-27 |
Family
ID=59416789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201900096QA SG11201900096QA (en) | 2016-07-07 | 2017-07-06 | Novel processes for preparation of soluble guanylate cyclase stimulators |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11319308B2 (ru) |
| EP (2) | EP4249488A3 (ru) |
| JP (1) | JP7112384B2 (ru) |
| KR (1) | KR102487872B1 (ru) |
| CN (1) | CN109563077A (ru) |
| AU (1) | AU2017291827B2 (ru) |
| BR (1) | BR112019000291A2 (ru) |
| CA (1) | CA3029375A1 (ru) |
| CL (2) | CL2019000016A1 (ru) |
| EA (1) | EA201990237A1 (ru) |
| ES (1) | ES2963563T3 (ru) |
| IL (1) | IL263995B (ru) |
| MA (1) | MA45603A (ru) |
| MX (2) | MX2019000105A (ru) |
| SG (1) | SG11201900096QA (ru) |
| WO (1) | WO2018009597A1 (ru) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10202100168XA (en) * | 2016-07-07 | 2021-02-25 | Cyclerion Therapeutics Inc | Novel processes for preparation of soluble guanylate cyclase stimulators |
| MA45603A (fr) | 2016-07-07 | 2019-05-15 | Ironwood Pharmaceuticals Inc | Nouveaux procédés de préparation de stimulateurs de la guanylate cyclase soluble |
| SG11202006311SA (en) | 2018-01-10 | 2020-07-29 | Cyclerion Therapeutics Inc | Novel processes and intermediates for the preparation of soluble guanylate cyclase stimulators |
| WO2019161534A1 (en) * | 2018-02-22 | 2019-08-29 | Ironwood Pharmaceuticals, Inc. | Novel processes and intermediates for preparation of soluble guanylate cyclase stimulators |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8969349B2 (en) | 2010-05-26 | 2015-03-03 | Sunovion Pharmaceuticals Inc. | Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors |
| WO2012003405A1 (en) | 2010-06-30 | 2012-01-05 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| EP2797915B1 (en) * | 2011-12-27 | 2016-07-13 | Ironwood Pharmaceuticals, Inc. | 2-benzyl-3-(oxazole/thiazole)-5-(pyrimidin-2-yl)-1(H)-pyrazole derivatives as stimulators of the soluble guanylate cyclase (sGC) for the treatment of e.g. hypertension or heart failure |
| EP2897953B8 (en) * | 2012-09-19 | 2019-06-26 | Cyclerion Therapeutics, Inc. | Sgc stimulators |
| SI3660013T1 (sl) * | 2013-03-15 | 2022-05-31 | Cyclerion Therapeutics, Inc. | SGC stimulatorji |
| EP3092231B1 (en) | 2013-12-11 | 2018-06-27 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| EP3194382B1 (en) * | 2014-09-17 | 2021-09-08 | Cyclerion Therapeutics, Inc. | Pyrazole derivatives as sgc stimulators |
| JP2017527604A (ja) * | 2014-09-17 | 2017-09-21 | アイアンウッド ファーマシューティカルズ インコーポレイテッド | ｓＧＣ刺激剤 |
| EP3194395B1 (en) * | 2014-09-17 | 2019-12-04 | Cyclerion Therapeutics, Inc. | Sgc stimulators |
| WO2016044445A2 (en) * | 2014-09-17 | 2016-03-24 | Ironwood Pharmaceuticals, Inc. | sGC STIMULATORS |
| EA201891315A1 (ru) | 2015-11-30 | 2018-12-28 | Айронвуд Фармасьютикалз, Инк. | Твердые дисперсии, содержащие стимулятор sgc |
| EP3481820B1 (en) | 2016-07-07 | 2023-10-18 | Cyclerion Therapeutics, Inc. | Solid forms of an sgc stimulator |
| MA45603A (fr) | 2016-07-07 | 2019-05-15 | Ironwood Pharmaceuticals Inc | Nouveaux procédés de préparation de stimulateurs de la guanylate cyclase soluble |
| SG10202100168XA (en) * | 2016-07-07 | 2021-02-25 | Cyclerion Therapeutics Inc | Novel processes for preparation of soluble guanylate cyclase stimulators |
| CA3086207A1 (en) * | 2017-12-19 | 2019-06-27 | Cyclerion Therapeutics, Inc. | Sgc stimulators |
| SG11202006311SA (en) * | 2018-01-10 | 2020-07-29 | Cyclerion Therapeutics Inc | Novel processes and intermediates for the preparation of soluble guanylate cyclase stimulators |
-
2017
- 2017-07-06 MA MA045603A patent/MA45603A/fr unknown
- 2017-07-06 US US16/315,218 patent/US11319308B2/en active Active
- 2017-07-06 BR BR112019000291A patent/BR112019000291A2/pt unknown
- 2017-07-06 SG SG11201900096QA patent/SG11201900096QA/en unknown
- 2017-07-06 EA EA201990237A patent/EA201990237A1/ru unknown
- 2017-07-06 MX MX2019000105A patent/MX2019000105A/es unknown
- 2017-07-06 EP EP23185002.5A patent/EP4249488A3/en active Pending
- 2017-07-06 JP JP2019500355A patent/JP7112384B2/ja active Active
- 2017-07-06 AU AU2017291827A patent/AU2017291827B2/en active Active
- 2017-07-06 CA CA3029375A patent/CA3029375A1/en active Pending
- 2017-07-06 KR KR1020197003459A patent/KR102487872B1/ko active IP Right Grant
- 2017-07-06 EP EP17745553.2A patent/EP3481818B1/en active Active
- 2017-07-06 ES ES17745553T patent/ES2963563T3/es active Active
- 2017-07-06 CN CN201780047020.6A patent/CN109563077A/zh active Pending
- 2017-07-06 WO PCT/US2017/040810 patent/WO2018009597A1/en unknown
-
2018
- 2018-12-27 IL IL263995A patent/IL263995B/en active IP Right Grant
-
2019
- 2019-01-04 CL CL2019000016A patent/CL2019000016A1/es unknown
- 2019-01-07 MX MX2022001495A patent/MX2022001495A/es unknown
-
2022
- 2022-03-30 US US17/708,296 patent/US11773089B2/en active Active
-
2023
- 2023-01-24 CL CL2023000228A patent/CL2023000228A1/es unknown
- 2023-08-24 US US18/237,435 patent/US20240059684A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220227748A1 (en) | 2022-07-21 |
| EP3481818B1 (en) | 2023-09-06 |
| WO2018009597A1 (en) | 2018-01-11 |
| EP4249488A2 (en) | 2023-09-27 |
| EA201990237A1 (ru) | 2019-08-30 |
| EP4249488A3 (en) | 2023-12-20 |
| EP3481818C0 (en) | 2023-09-06 |
| BR112019000291A2 (pt) | 2019-04-16 |
| US11773089B2 (en) | 2023-10-03 |
| MA45603A (fr) | 2019-05-15 |
| CN109563077A (zh) | 2019-04-02 |
| KR20190025986A (ko) | 2019-03-12 |
| CL2023000228A1 (es) | 2023-09-29 |
| CL2019000016A1 (es) | 2019-05-03 |
| EP3481818A1 (en) | 2019-05-15 |
| US20240059684A1 (en) | 2024-02-22 |
| ES2963563T3 (es) | 2024-03-27 |
| JP2019525913A (ja) | 2019-09-12 |
| MX2019000105A (es) | 2019-04-22 |
| KR102487872B1 (ko) | 2023-01-12 |
| IL263995A (en) | 2019-02-28 |
| IL263995B (en) | 2021-02-28 |
| US20210323951A1 (en) | 2021-10-21 |
| CA3029375A1 (en) | 2018-01-11 |
| MX2022001495A (es) | 2022-03-11 |
| AU2017291827B2 (en) | 2021-10-21 |
| US11319308B2 (en) | 2022-05-03 |
| AU2017291827A1 (en) | 2019-02-07 |
| JP7112384B2 (ja) | 2022-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| SG11201809559UA (en) | Substituted pyridines as inhibitors of dnmt1 | |
| SG11201810683VA (en) | Process for preparing n-(5-(3-(7-(3-fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide | |
| SG11201903908PA (en) | Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201908670SA (en) | Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators | |
| SG11201903487SA (en) | PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF | |
| SG11201900096QA (en) | Novel processes for preparation of soluble guanylate cyclase stimulators | |
| SG11201808582RA (en) | Pyrrolotriazine compounds as tam inhibitors | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201805380YA (en) | Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapy | |
| SG11201805514VA (en) | Processes for the preparation of 2,5-furandicarboxylic acid and intermediates and derivatives thereof | |
| SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
| SG11201407533SA (en) | Antiviral compounds | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201805595TA (en) | Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1h-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid | |
| SG11201809830WA (en) | Selective reduction of cysteine-engineered antibodies | |
| SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
| SG11201805387RA (en) | Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201907364WA (en) | Anti-tryptase antibodies, compositions thereof, and uses thereof | |
| SG11201804885TA (en) | Monomaleimide-functionalized platinum compounds for cancer therapy |